Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth Prevenar Approval Expected By End of February

Executive Summary

Wyeth-Ayerst is expecting approval of its pneumococcal conjugate vaccine Prevenar by the end of February.

You may also be interested in...



Wyeth Protonix I.V. Indicated As Second-Line Therapy After Oral Pantoprazole

Wyeth-Ayerst's intravenous proton pump inhibitor Protonix will be launched in mid-April as a second-line alternative to Protonix (pantoprazole) tablets.

Wyeth Protonix I.V. Indicated As Second-Line Therapy After Oral Pantoprazole

Wyeth-Ayerst's intravenous proton pump inhibitor Protonix will be launched in mid-April as a second-line alternative to Protonix (pantoprazole) tablets.

EMEA Clears Four Biologics In 1999 Before FDA, And Five Later Than FDA

The European Medicines Evaluation Agency approved four biological products in 1999 that have not yet been licensed by FDA.

Related Content

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel